Ripple Therapeutics

About

Ripple Therapeutics Corporation is a clinical-stage ophthalmic biotech company based in Toronto, Ontario. Founded in January 2020, the company specializes in developing controllable, sustained-release drug delivery implants for various eye diseases, including glaucoma, diabetic macular edema, and retinal vein occlusion. Ripple's innovative Epidel technology platform creates fully biodegradable implants that offer customizable dosing and improved safety compared to traditional treatments. The company's product pipeline includes IBE-814, a dexamethasone implant that has shown promising results in clinical trials, a glaucoma implant with confirmed safety and efficacy, and RTC-620, a next-generation implant designed for open-angle glaucoma. Ripple has established strategic partnerships with major players in eye health, such as AbbVie and Bausch + Lomb, to enhance its development efforts and expand its impact in ophthalmic care. With a dedicated team of about 26 employees, Ripple is focused on addressing the growing need for effective alternatives to conventional eye treatments.